Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Pharmacogenomics. 2015 Dec 15;17(2):147–162. doi: 10.2217/pgs.15.156

Table 3.

Primers combinationsfor CYP2A6 genotyping real-time PCR genotyping (Method 2.1 and 2.2)

Assay Primer Name Locationa Direction Sequence
First amplifications
5′ region template: 2A65Pr1F 5′ flanking (−1417) F ACC TAG ACT TAA TCT TCC CGT ATA C
CYP2A6*9, *31, *24, *20, *23 2A6in5R Intron 5 (3638) R GGC CTG TGT CAT CTG CCT
Modified 5′ region: 2Ain1F-L Intron 1 (316) F GAT CTT GGG ATG TCC AGC TCC
CYP2A6*12, *34 2A6in5R Intron 5 (3638) R GGC CTG TGT CAT CTG CCT
3′ region template: 2A6in6F1 Intron 6 (4892) F ATTTCCTGCTCTGAGACC
CYP2A6*17, *35, *1B 2A6R13 3′ flanking (8548) R GCC TCC CAT AGT GCT ATA ATT AAC A

Second amplifications
CYP2A6*9 2A6*9wtR-Sybr-Mb 5′ flanking (−29) R GCT GGG GTG GTT TGC CTC TA
2A6*9vR-Sybr-Mb 5′ flanking (−29) R GCT GGG GTG GTT TGC CTC TC
125M13BEV-B 5′ flanking (−146) F CCC AAG CTA GGC AGG ATT CAT G

CYP2A6*31 2A6*31wtR-Sybr Exon 1 (35) R AGC AAG GCC ACC AGA AGC AT
2A6*31vR-Sybr Exon 1 (35) R AGC AAG GCC ACC AGA AGC AG
2A61F-L Exon 1 (−155) F TGG CTG TGT CCC AAG CTA GGC A

CYP2A6*24 2A6*24wtR-Sybr-Mb ExIn 2 (619) R ACC CCC TCA CCA TAG CCT TTG AAT AC
2A6*24vR-Sybr-Mb ExIn 2 (619) R ACC CCC TCA CCA TAG CCT TTG AAT AG
2A6ex2-505F Exon 2 (505) F TGC TGT GTG GAC ATG ATG CCG TCA G

CYP2A6*20 2A6*20wtR-sybr-Mb Exon 4 (2160) R CAA CAG TGA CAG GAA CTC TTT GTA CT
2A6*20vtR-sybr-Mb Exon 4 (2160) R CAA CAG TGA CAG GAA CTC TGT ACT
2A6in3F-L Intron 3 (1967) F CCC TGC CTC CTG GAA TTC TGA C

CYP2A6*23 2A6ex42161Fw-Mb Exon 4 (2139) F CAA AGA GTT CCT GTC ACT GTC GC
2A6ex42161Fv-M-Lb Exon 4 (2137) F GA CAA AGA GTT CCT GTC ACT GTC GT
5M13FOR-H2 Intron 4 (2260) R GCA GTT GGC AGG TTG TGG TAG G

CYP2A6*12 2A6in1/ex2-L In1/Ex2 (434) F CCACCTCCATCAGATCAGTGAGC
2A7in1/ex2-L In1/Ex2 (952) F TCGCCTCCATCAGTTCAGTGAGT
2A6R-667 Intron 2 (667) R GAACACTGAGACCTTCGTGTCCA

CYP2A6*34 2A6-2572F Intron 4 (2572) F TCAACCGGCCTCCTGCATA
2A7-2978F Intron 4 (2978) F AAC CCG CCT CCT GCA TG
2A6-2862R Intron 4 (2862) R GTTTACCTATCCAAGTGGGATGCACT

CYP2A6*17 2A6*17Fwt-Sybr-Mb Exon 7 (5042) F ACG AGA TCC AAA GAT TTG GAG CCG
2A6*17Fv-Sybr-Mb Exon 7 (5042) F ACG AGA TCC AAA GAT TTG GAG CCA
2A6in7-17R2 Intron 7 (5198) R GGA TGC TGG GGA CAC AGA GAG

CYP2A6*35 2A6*35wtR-Sybr Exon 9 (6479) R CCA GGC CTT CTC CGA AAC AGT T
2A6*35vR-Sybr Exon 9 (6479) R CCA GGC CTT CTC CGA AAC AGT A
2A6in8-6395F Intron 8 (6395) F CGA GGC TGC ACT GAG AGT GG

CYP2A6*1B 2A6*1Bwt 3′ flanking (6719) F ACT GGG GGC AGG ATG GC
2A6*1Bvar-L 3′ flanking (7101) F GGG TAT AAG AAT GGG GGG AAG ATG CG
2A6R6944 3′ flanking (6944) R GTG GCA ATT AGG TGA GCG TGC AAT G
a

CYP2A6 primer position is based on CYP2A6 +1ATG, and CYP2A7 primer position is based on CYP2A7 +1ATG

b

Mismatch primer at third position from 3′end, underlined in sequence